QHSLab (OTCQB: USAQ) Q2 revenue jumps 40% as ISP and margins grow
Rhea-AI Filing Summary
QHSLab, Inc. reported unaudited results for the three and six months ended June 30, 2026, showing strong growth in its Integrated Service Program (ISP). In Q2 2026, ISP revenue rose 86.4% to $491,399, while total revenue increased 40.1% to $847,490. Gross profit was $589,784 and gross margin expanded to 69.6%. Operating income increased to $45,245, and net income was $38,030, compared with a net loss of $52,958 a year earlier.
For the first half of 2026, total revenue grew 26.0% to $1,576,175, with ISP revenue up 103.2% to $865,900, representing roughly 55% of revenue. Gross profit reached $1,060,587 and gross margin improved to 67.3%. Interest expense declined 87.3% to $16,741 following retirement of substantially all legacy convertible debt, and the net loss narrowed to $65,876 from $132,567. Management emphasized the growing recurring, software-enabled revenue base and lower financing costs as evidence of improving operating leverage.
Positive
- Q2 2026 net income of $38,030 versus a prior-year net loss of $52,958 signals a return to quarterly profitability alongside 40.1% revenue growth to $847,490.
- Integrated Service Program revenue grew 86.4% in Q2 to $491,399 and 103.2% in the first half to $865,900, becoming roughly 55% of total revenue and strengthening the recurring revenue mix.
- Interest expense fell 87.3% to $16,741 in the first half of 2026 after the retirement of substantially all legacy convertible debt, reducing financing drag on future earnings.
Negative
- Despite improvements, QHSLab recorded a first-half 2026 net loss of $65,876, following a $132,567 loss in the prior-year period, indicating profitability has not yet been achieved on a year-to-date basis.
8-K Event Classification
Key Figures
Key Terms
Integrated Service Program financial
gross margin financial
convertible debt financial
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were QHSLab (USAQ)'s Q2 2026 revenues and profit?
How did QHSLab (USAQ)'s Integrated Service Program perform in Q2 2026?
What were QHSLab (USAQ)'s first-half 2026 financial highlights?
How much did QHSLab (USAQ)'s interest expense decline in the first half of 2026?
What happened to QHSLab (USAQ)'s gross margins in Q2 and first half 2026?
How important is ISP revenue to QHSLab (USAQ)'s overall business?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(Commission File No.)
(State of Incorporation) |
(I.R.S. Employer Identification No.) | |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On August 3, 2026, QHSLab, Inc. (the “Company”) issued a press release titled “QHSLab (OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in the press release annexed as Exhibit 99.1 is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.
We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 3, 2026 – QHSLab (OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: August 3, 2026 | ||
| QHSLab, Inc. | ||
| /s/ Troy Grogan | ||
| Name: | Troy Grogan | |
| Title: | CEO and Chairman | |
Exhibit 99.1
QHSLab (OTCQB:USAQ) Reports Second Quarter and First Half 2026 Unaudited Financial Results
Integrated Service Program (ISP) Revenue More Than Doubles Year-over-Year as Gross Margins Expand and Financing Costs Decline
West Palm Beach, FL, August 3, 2026 (GLOBE NEWSWIRE) — QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology and software-as-a-service (SaaS) company focused on enabling primary care providers to improve patient outcomes while increasing practice revenue through reimbursable preventive care, digital health and clinical decision support solutions, today reported its unaudited financial results for the three and six months ended June 30, 2026.
Management believes the second quarter reflects continued momentum in the Company’s strategic transition toward recurring revenue, software-enabled healthcare platform, led by strong growth in its Integrated Service Program (“ISP”), expanding gross margins and significantly reduced financing costs.
Second Quarter 2026 Financial Highlights
For the three months ended June 30, 2026:
| ● | ISP revenue increased 86.4% to $491,399, compared with $263,628 during the second quarter of 2025. | |
| ● | Total revenue increased 40.1% to $847,490, compared with $605,446 in the prior-year quarter. | |
| ● | Gross profit increased 47.8% to $589,784, compared with $399,015. | |
| ● | Gross margin expanded to 69.6%, compared with 65.9% in the second quarter of 2025. | |
| ● | Operating income increased to $45,245, compared with $11,526 in the prior-year quarter. | |
| ● | Net income improved to $38,030, compared with a net loss of $(52,958) during the second quarter of 2025. |
First Half 2026 Financial Highlights
For the six months ended June 30, 2026:
| ● | Total revenue increased 26.0% to $1,576,175, compared with $1,250,865 during the first six months of 2025. | |
| ● | ISP revenue increased 103.2% to $865,900, compared with $426,130 in the prior-year period. | |
| ● | Gross profit increased 27.9% to $1,060,587, compared with $828,959. | |
| ● | Gross margin improved to 67.3%, compared with 66.3% in the prior-year period. | |
| ● | Interest expense declined 87.3% to $16,741, compared with $132,054, reflecting the Company’s strengthened balance sheet following the retirement of substantially all legacy convertible debt. | |
| ● | Net loss improved approximately 50% to $(65,876) compared with $(132,567) during the first six months of 2025, despite continued investment in product development, sales and organizational infrastructure. |
Although the Company reported a net loss for the six-month period, management believes the combination of accelerating recurring ISP revenue, expanding gross margins and significantly lower financing costs demonstrates continued progress toward improved operating leverage.
Management Commentary; Business Update
“Our second quarter results demonstrate the evolution of QHSLab into a scalable healthcare technology platform built on recurring provider relationships,” said Troy Grogan, President and Chief Executive Officer of QHSLab.
“ISP revenue more than doubled during the first half of 2026 and was our primary source of revenue during the period, increasing to $865,900, or approximately 55% of total revenue, and continues to become a larger component of our overall revenue mix. We believe this reflects increasing provider recognition of the clinical and financial value of integrating preventive health screening and digital engagement into everyday patient care.
Equally important, we continue to generate strong gross margins while investing in the technology, software and organizational infrastructure necessary to support our long-term growth strategy. During the first half of 2026, we expanded our ISP platform by adding additional software-enabled healthcare solutions designed to improve patient engagement, preventive and chronic care delivery and recurring revenue opportunities.
Looking ahead, our priorities remain clear: expanding provider acquisition, accelerating provider activation, and investing in product innovation to increase recurring software-enabled revenue. We believe the investments we are making today are the foundation for a highly scalable healthcare platform capable of delivering meaningful long-term value for healthcare providers and our shareholders.
While we remain focused on improving our business, during the past nine months we substantially strengthened our balance sheet through the retirement of convertible debt, significantly reducing financing costs, improving our financial flexibility and our capital markets profile.”
Financial results included in this release are unaudited.
For additional information, including the Company’s latest corporate presentation, please visit the QHSLab investor relations website at https://www.qhslab.com/for-investors
About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health infrastructure company supporting independent primary care practices through workflow-integrated digital screening, clinical decision support, and care management services. The Company’s platform is designed to help physicians identify and manage underdiagnosed behavioral health and chronic conditions while supporting reimbursable clinical activities that occur both during and outside traditional office visits. QHSLab generates revenue primarily through recurring service fees from participating medical practices. The Company also operates an allergy diagnostics and treatment service line under the AllergiEnd® brand. Learn more at www.qhslab.com
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc